Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue 4, 2005, Pages 257-262

  Hochster, Howard ^a,k   Kettner, Erika ^b   Kröning, Hendrik ^c   Becker, Klaus ^d   Lordick, Florian ^e   Ramanathan, Ramesh K ^f   Macdonald, John ^g   Hong, Shengyan ^h   John, William ⁱ   Schmoll, Hans Joachim ^j  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Stadisches Klinikum Magdeburg   (Germany)

^c Schwerpunktpraxis für Haematologie und Onkologie Hasselbachplatz   (Germany)

^d Innovation Onkologie Research and Consulting GmbH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^h ELI LILLY AND COMPANY   (United States)

ⁱ Commonwealth Cancer Center ^*  (United States)

^j MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^k NEW YORK UNIVERSITY   (United States)

more..

Author keywords

Combination therapy; FOLFIRI; Metastases; Vitamin supplementation

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CYANOCOBALAMIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PEMETREXED; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; VITAMIN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; VOMITING; CANCER STAGING; COLORECTAL TUMOR; DIET SUPPLEMENTATION; MIDDLE AGED; PATHOLOGY; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TIME FACTORS; TREATMENT OUTCOME; VITAMINS;

EID: 33644840299     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.036     Document Type: Article

References (25)

1. The American Cancer Society [Website]. Cancer Statistics Presentation 2005. Available at: retrieved 11/11/05. http://americancancersociety.org/ docroot/pro/content/pro_1_1_cancer_statistics_2005_presentation.asp. Accessed October 11, 2005.
2. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122:598-609.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
4. Hofheinz R, Hartung G, Samel S, et al. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer - a phase II study. Anticancer Drugs 2002; 13:999-1004.
5. Rougier P, Lepille D, Bennouna J, et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002; 13:1558-1567.
6. Hanna NH. Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed. Clin Lung Cancer 2004; 5(suppl 2):S75-S79.
7. Kut V, Patel JD, Argiris A. Pemetrexed: A novel antifolate agent enters clinical practice. Expert Rev Anticancer Ther 2004; 4:511-522.
8. Teicher BA, Alvarez E, Lu K, et al. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999; 26(suppl 2):S55-S62.
9. Tsuji T, Kaneda N, Kado K, et al. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991; 14:341-349.
10. Morton CL, Wadkins RM, Danks MK, et al. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 1999; 5:1458-1463.
11. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361:2235-2242.
12. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatiic colorectal carcinoma. J Clin Oncol 1997; 15:2910-2919.
13. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11:909-913.
14. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
15. Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
16. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 905-914.
17. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
18. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239-253.
19. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1:545-552.
20. Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13:2842-2850.
21. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
22. Andre T, Boni C, Mounedji-Boudiaf L, et. al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
23. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. J Clin Oncol 2005; 23(16 suppl):246s (Abstract #LBA3500).
24. Ychou M, Raoul J, Douillard J, et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol 2005; 23(16 suppl):246s (Abstract #3502).
25. Van Cutsem E, Labianca R, Hossfled D, et. al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). J Clin Oncol 2005; 23(16 suppl):3s (Abstract #LBA8).